Agustin Pappolla, Cristina Auger, Augusto Sao-Aviles, Carmen Tur, Marta Rodriguez-Barranco, Álvaro Cobo-Calvo, Neus Mongay-Ochoa, Breogán Rodríguez-Acevedo, Ana Zabalza, Luciana Midaglia, Pere Carbonell-Mirabent, Rene Carvajal, Joaquín Castilló-Justribó, Nathane Braga, Luca Bollo, Angela Vidal-Jordana, Georgina Arrambide, Carlos Nos, Annalaura Salerno, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Alex Rovira, Xavier Montalban, Jordi Río
BACKGROUND: Limited data exist regarding treatment response prediction to oral disease-modifying therapies (DMTs) in multiple sclerosis (MS). OBJECTIVES: We assessed the capacity of available scoring systems to anticipate disease activity parameters in naïve relapsing-remitting MS (RRMS) patients initiating daily oral DMTs, hypothesizing that they exhibit different predictive potentials. METHODS: We conducted a retrospective study and applied the Rio Score (RS), modified Rio Score (mRS), and MAGNIMS Score 12 months after DMT initiation...
March 29, 2024: Multiple Sclerosis: Clinical and Laboratory Research